ESTRO 2025 - Abstract Book

S1331

Clinical - Lung

ESTRO 2025

With a median follow-up of 35 months (range, 6-117 mo), 28 treated lesions locally progressed (8%), with a 3, 5 and 8 years local control (LC) 3 rate of 92% (95% CI 88-95), 86% (95% CI 82-92), 85% (95% CI 78-91) respectively (Fig 1). Eighteen patients (5%) experienced regional failure 3 . Distant control (DC) 3 at 3, 5 and 8 years was 82%, (95% CI 77-87), 70% (95% CI 63-77), 62% (95% CI 54-72), respectively. No statistically significant differences in terms of LC (Fig 1) and DC were observed between patients with or without histological diagnosis. Overall Survival (OS) at 3, 5 and 8 years were 63% (95% CI 58-69), 47% (95% CI 41-54) and 21% (95% CI 15-29), respectively. Median OS of patients with or without histological diagnosis was 70 months (95% CI 58-91) and 49 months (95% CI 39-60) (p= 0.002), respectively. Most frequent causes of death were comorbidities (83%). No severe acute toxicities were recorded. Late Grade 3 pneumonitis and late grade 1-2 rib fractures, were observed in 3 (0.9%) and 11 patients (3%), respectively.